Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | ADCY1 | Q08828 | 2/20 | 0.32 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.32 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 2/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.31 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL408292 | 1.00 | EPHX2 (0.37) | EPHX2NPC1RAB9AADCY1AKR1C3 | |
| SCHEMBL408394 | 0.85 | NPC1 (0.42) | EPHX2NPC1RAB9AADCY1AKR1C3 | |
| SCHEMBL439761 | 0.85 | NPC1 (0.42) | EPHX2NPC1RAB9AADCY1AKR1C3 | |
| SCHEMBL29988103 | 0.83 | EPHX2 (0.35) | EPHX2NPC1RAB9AADCY1AKR1C3 | |
| SCHEMBL408392 | 0.83 | EPHX2 (0.37) | EPHX2ADCY1 | |
| SCHEMBL441162 | 0.83 | EPHX2 (0.37) | EPHX2ADCY1 | |
| SCHEMBL440024 | 0.78 | TNKS (0.39) | EPHX2NPC1RAB9AADCY1AKR1C3 | |
| SCHEMBL408425 | 0.78 | TNKS (0.39) | EPHX2NPC1RAB9AADCY1AKR1C3 | |
| SCHEMBL29988313 | 0.77 | PDK2 (0.34) | EPHX2NPC1RAB9AADCY1AKR1C3 | |
| SCHEMBL29988165 | 0.75 | AKR1C3 (0.34) | EPHX2NPC1RAB9AADCY1AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065196-A1 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-15 | — | — | US | disclosed |
| WO-2008011130-A2 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065196-A1 | AMIDE COMPOUNDS | DGAT2, DGAT1, DLAT | EPHX2 1660/4885NPC1 142/4885RAB9A 1525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.